

HER2- Low Metastatic Breast Cancer: Interpretation & Treatment Glossary

1L, first line
2L, second line
3L, third line
ADC, antibody-drug conjugate
AE, adverse event
AI, aromatase inhibitor
BC, breast cancer
BICR, blinded independent central review
C-GSF, granulocyte colony-stimulating factor
CPS, combined positive score
CT, computed tomography
Dato-DXd, datopotamab deruxtecan
ddAC, dose-dense doxorubicin plus dose-dense cyclophosphamide
EGFR, epidermal growth factor receptor
ER, estrogen receptor
ET, endocrine therapy
GATA3, GATA-binding protein 3
gBRCA, germline BRCA mutations
G-CSF, granulocyte colony-stimulating factor
HER2-, human epidermal growth factor receptor negative
HR-, hormone receptor negative
IHC, immunohistochemistry
ILD, interstitial lung disease
ISH, in situ hybridization
ITT, intention-to-treat
LN, lymph node
mBC, metastatic breast cancer
mOS, median overall survival
mPFS, median progression-free survival
MSS, microsatellite stable
mTNBC, metastatic triple-negative breast cancer
mut/Mb, mutations/Megabase
NCCN, National Comprehensive Cancer Network
ORR, objective response rate
OS, overall survival
PFS, progression-free survival
PR, progesterone receptor
SBO, small bowel obstruction
SG, sacituzumab govitecan
T-DXd, trastuzumab deruxtecan
TMB, tumor mutational burden
TNBC, triple-negative breast cancer
TPC, treatment of physician's choice
TROP2, trophoblast cell surface antigen 2
WES, whole-exome sequencing